What happens after stopping Mounjaro: the evidence

What clinical trials found when participants stopped tirzepatide

The clearest evidence comes from the SURMOUNT-1 extension, where participants who had lost significant weight on tirzepatide were then observed after stopping treatment. Appetite returned, caloric intake rose, and a substantial portion of lost weight was regained over the following months. This mirrors what the SURMOUNT-1 paper in the New England Journal of Medicine documented: the average weight reductions achieved during active treatment were not sustained once the drug was withdrawn without structured support.

The mechanism explains why. Tirzepatide is a dual GIP and GLP-1 receptor agonist that slows gastric emptying and reduces appetite signalling while it is active in the body. Remove that signal and the body's own hunger hormones reassert themselves. For many people that reassertion feels abrupt, even if the pharmacological effect fades over a week or two. Weight does not rush back overnight, but the trajectory often reverses within the first few months of stopping, and our guide to what happens when you stop Mounjaro walks through what that process typically looks like.

This is not a failure unique to tirzepatide. The same pattern emerged with semaglutide in the STEP 1 programme. Both bodies of evidence point to the same conclusion: obesity is a chronic condition, and medicines that manage it tend to work only while they are being taken. That framing is now reflected in NHS and NICE guidance, which considers these treatments in a long-term, not one-course, context. You can read more about the evidence base on the Mounjaro treatment overview.

What your body goes through in the weeks after the last injection

A question our prescribers hear most weeks is: "Will I put all the weight back on straight away?" The honest answer is: not immediately, but the risk is real and the timeline is shorter than most people expect.

In the days after the last dose, tirzepatide concentration in the blood falls progressively; its half-life means it is largely cleared within two to three weeks. Hunger signals tend to increase before the medicine has fully left the system, which can feel disorienting for people who experienced markedly reduced appetite on treatment. Gastric emptying returns to its pre-treatment speed, portion tolerance changes, and some people notice cravings for foods they had found easy to avoid.

Metabolic rate also plays a role. Weight loss itself, regardless of how it is achieved, reduces resting energy expenditure, the body burns fewer calories at a lower weight. This effect persists after stopping tirzepatide and makes maintaining the lower weight harder without the appetite suppression the medicine provided. The NHS patient page on tirzepatide notes that treatment should be used alongside a reduced-calorie diet and increased physical activity; those lifestyle changes become even more important once medication stops.

For a fuller picture of the physical changes involved, the body changes after Mounjaro guide covers the physiology in more detail.

How to approach stopping in a way that reduces regain risk

There is no clinically established Mounjaro tapering protocol in the way that exists for some other medicines; the SmPC does not specify a mandatory reduction schedule. What clinical guidance does emphasise is that stopping should be a planned, supervised decision rather than an abrupt one driven by cost, supply, or side-effect fatigue without discussion.

Speaking with your prescriber before stopping gives you the chance to review whether a lower maintenance dose might be a better option than full cessation, to consolidate any dietary and activity habits built during treatment, and to understand what signs of significant regain would warrant restarting. People who used the treatment period to build durable habits around protein intake, portion awareness and regular movement tend to maintain more of their loss than those who relied on the medicine alone.

If you are weighing the ongoing cost of private treatment, the Mounjaro cost guide sets out what a realistic private prescription includes. And if you have stopped and are considering restarting, that too is a clinical conversation rather than simply reordering; a prescriber would want to review your current weight, any changes in health, and whether the original treatment plan still fits. You can also find guidance on what changes after the course ends at this overview of stopping tirzepatide.

The bigger picture: planning treatment with the long term in mind

NICE's appraisal of tirzepatide, TA1026, acknowledges that ongoing treatment is likely to be needed to maintain benefit, and that people who do not achieve at least 5% weight loss after six months at the highest tolerated dose should have continuing treatment reviewed. That framing, built into national guidance, reflects the chronic-disease model: these medicines are not a course with a natural end point in the way a course of antibiotics is.

For many people, the question is less "how do I stop?" and more "how do I stay supported, whether or not I'm on the medicine?" Structured clinical follow-up, a realistic understanding of what regain looks like, and a plan for how to respond to it are as much a part of treatment as the injections themselves. If you are approaching the end of a course, or if circumstances have changed and stopping feels like the only option, our guide to what happens after Mounjaro is a useful starting point before your conversation with a prescriber rather than a quiet last injection.

If you are exploring your options around ongoing or future treatment, our weight-loss treatment overview explains what is currently available through a private regulated pathway. For questions that do not fit a standard page, our FAQ section covers the most common ones, and our contact page connects you with the team directly.